We are pleased to announce that Dr. Jörg Taubel, will be one of the faculty members at the upcoming course tailored for postgraduates in life sciences interested in early clinical development of medicinal products.
This comprehensive course consists of two parts, spanning several days, providing an in-depth overview of Human Pharmacology and Translational Medicine. The curriculum covers essential topics from non-clinical pharmacology and toxicology to first-in-man studies and proof-of-concept clinical trials.
Richmond supports Beam Therapeutics to make significant step forward in potential one-time gene editing treatment for Alpha-1
March 30, 2026
Beam Therapeutics has announced compelling updated clinical data from its ongoing Phase 1/2 Trial of BEAM-302 as a potential treatment for Alpha-1 Antitrypsin Deficiency (AATD).
By clicking “Accept”, you agree to the storing of cookies on your device to enhance site navigation, analyze site usage, and assist in our marketing efforts. View our Privacy Policy for more information.
.svg){kind=small}
.avif)
